Last edition
News about "Dietmar Berger"
US FDA Accepts Gilead's Once-Weekly Yeztugo for HIV Prevention
Gilead’s investigational once-weekly oral HIV prevention pill Yeztugo has been accepted for US FDA review, supported by strong clinical data showing high efficacy of lenacapavir in preventing HIV across 2 clinical trials. The therapy could become the first long-acting oral option for HIV prevention.
Dietmar Berger | 16/06/2026 | By News Bureau
Gilead Sciences Wins FDA Accelerated Approval for First HDV Treatment Hepcludex
Gilead Sciences receives Food and Drug Administration (FDA) accelerated approval for Hepcludex, the first and only approved treatment for chronic Hepatitis Delta Virus (HDV), addressing a major unmet need in severe viral hepatitis care.
Dietmar Berger | 26/05/2026 | By News Bureau
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Dietmar Berger | 22/05/2026 | By News Bureau | 511
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy